on Lobe Sciences Ltd. (CVE:LOBE)
Lobe Sciences Appoints New Chief Medical Officer
On October 20, 2026, Lobe Sciences Ltd. announced the appointment of Dr. Tracy L. Goeken as Chief Medical Officer. Lobe Sciences, a clinical-stage biopharmaceutical company, focuses on therapies for neurological conditions and rare diseases. Dr. Goeken's prior experience includes serving as Chief Medical Officer at Linical, a global clinical research organization.
Dr. Frederick D. Sancilio, Chairman and CEO of Lobe Sciences, emphasized Dr. Goeken's relevant expertise in clinical development and regulatory strategy. Dr. Goeken will contribute significantly to advancing Lobe's key programs, such as L-130 for generalized anxiety disorder and S-100 for sickle cell disease.
In addition, Lobe Sciences engaged Independent Trading Group (ITG), Inc. to provide market-making services, aiming to support a fair market. The initial agreement is for C$6,000 per month, with monthly renewals.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Lobe Sciences Ltd. news